AbbVie Responds to COVID-19 Global Pandemic with $35 Million Donation

In response to the COVID-19 pandemic, AbbVie is collaborating with select health authorities and institutions globally on clinical research related to COVID-19. AbbVie is supporting clinical studies and basic research, working closely with European health authorities and the U.S. Food and Drug Administration, Centers for Disease Control and Prevention, National Institutes of Health and Biomedical Advanced Research and Development Authority to coordinate on their efforts.

Additionally, AbbVie is donating $35 million to help support underserved communities and healthcare systems working to address the impact of the COVID-19 global pandemic. AbbVie’s partners are:

• International Medical Corps to help create capacity to treat patients at overburdened hospitals. AbbVie’s donation will support the creation and operation of mobile field hospitals in the United States that will provide capacity and create improved patient flow options as hospitals work to keep COVID-19 patients separated from other patients.

• Direct Relief to help meet healthcare system needs in the hardest hit countries. This support will enable the procurement and delivery of oxygen concentrators, ventilators and personal protective equipment to healthcare systems and prioritize countries with high infection rates, beginning with Italy, the UK, France and Spain.

• Feeding America to protect the most vulnerable, including the elderly, by enabling access to food and essential household supplies with minimal contact. Feeding America has created a new model of home delivery and drive-through service.

Included in the $25 million is a reserve of $5 million for a new AbbVie COVID-19 Community Resilience Fund. The Fund will provide up to $1 million in financial support to organizations strengthening community resilience in under-resourced areas impacted by COVID-19.

To read more, including information on supply chain and production, patients taking AbbVie medications, healthcare workers, AbbVie employees and clinical trial impact, visit AbbVie’s website.